CN110279684B - 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途 - Google Patents

用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途 Download PDF

Info

Publication number
CN110279684B
CN110279684B CN201910497947.0A CN201910497947A CN110279684B CN 110279684 B CN110279684 B CN 110279684B CN 201910497947 A CN201910497947 A CN 201910497947A CN 110279684 B CN110279684 B CN 110279684B
Authority
CN
China
Prior art keywords
urea
bromophenyl
dioxo
ethyl
imidazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910497947.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110279684A (zh
Inventor
V·维斯瓦纳斯
R·L·比尔德
J·E·多纳罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN110279684A publication Critical patent/CN110279684A/zh
Application granted granted Critical
Publication of CN110279684B publication Critical patent/CN110279684B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910497947.0A 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途 Active CN110279684B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361773773P 2013-03-06 2013-03-06
US61/773,773 2013-03-06
PCT/US2014/020245 WO2014138037A1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
CN201480012204.5A CN105007909B (zh) 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480012204.5A Division CN105007909B (zh) 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Publications (2)

Publication Number Publication Date
CN110279684A CN110279684A (zh) 2019-09-27
CN110279684B true CN110279684B (zh) 2023-02-28

Family

ID=50382628

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910497947.0A Active CN110279684B (zh) 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
CN201480012204.5A Active CN105007909B (zh) 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480012204.5A Active CN105007909B (zh) 2013-03-06 2014-03-04 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Country Status (20)

Country Link
US (3) US9850264B2 (enExample)
EP (2) EP2964213B1 (enExample)
JP (4) JP6196327B2 (enExample)
KR (2) KR102227201B1 (enExample)
CN (2) CN110279684B (enExample)
AR (1) AR095034A1 (enExample)
AU (3) AU2014225992B2 (enExample)
BR (2) BR112015021371B1 (enExample)
CA (2) CA3133264A1 (enExample)
CL (3) CL2015002485A1 (enExample)
ES (2) ES2835825T3 (enExample)
IL (3) IL241012B (enExample)
MX (2) MX364916B (enExample)
MY (1) MY207109A (enExample)
PH (3) PH12020500285B1 (enExample)
RU (2) RU2768730C2 (enExample)
SG (2) SG11201507113RA (enExample)
TW (1) TWI616200B (enExample)
WO (1) WO2014138037A1 (enExample)
ZA (1) ZA201505134B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012329098B2 (en) * 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
SG11201406629VA (en) * 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
TW201348219A (zh) 2012-05-16 2013-12-01 Actelion Pharmaceuticals Ltd 作爲ａｌｘ受體激動劑之經１－（對－甲苯基）環丙基取代橋聯螺［２．４］庚烷衍生物
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN110279684B (zh) * 2013-03-06 2023-02-28 阿勒根公司 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
JP6196328B2 (ja) 2013-03-06 2017-09-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
US9428549B2 (en) * 2013-07-16 2016-08-30 Allegran, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
ES2639798T3 (es) 2013-07-18 2017-10-30 Idorsia Pharmaceuticals Ltd Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
ES2788700T3 (es) 2014-05-21 2020-10-22 Allergan Inc Derivados de imidazol como moduladores del receptor de péptido formilado
WO2016149667A1 (en) 2015-03-19 2016-09-22 University Of Maryland , Baltimore Runx2 transcription factor inhibitors and uses thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
JP7032323B6 (ja) * 2016-03-28 2023-12-18 アラーガン、インコーポレイテッド Ｎ－ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体
AU2017249047B2 (en) * 2016-04-12 2021-08-05 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
CN109843283B (zh) 2016-10-06 2022-08-30 第一三共株式会社 脲衍生物
CN109134533B (zh) 2017-06-27 2020-08-11 维眸生物科技（上海）有限公司 一种含磷化合物及其制备和应用
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
RU2712229C2 (ru) * 2018-05-17 2020-01-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
JP2022151437A (ja) * 2021-03-26 2022-10-07 均 石井 網膜炎治療薬。
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE60328202D1 (de) * 2002-09-05 2009-08-13 Neurosearch As Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
AU2003277575A1 (en) * 2002-11-07 2004-06-07 Takeda Pharmaceutical Company Limited Novel fprl1 ligands and use thereof
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20060130064A (ko) 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20080008694A1 (en) * 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US8349801B2 (en) * 2006-09-18 2013-01-08 Compugen Ltd. Peptide ligands for G-protein coupled receptors
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
WO2010104307A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
AU2012214265A1 (en) 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2839735A1 (en) 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
WO2013009543A1 (en) * 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
AU2012329098B2 (en) * 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2013221749A1 (en) 2012-02-16 2014-09-11 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators
SG11201406629VA (en) 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CN110279684B (zh) 2013-03-06 2023-02-28 阿勒根公司 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gastrin-Releasing Peptide/Neuromedin B Receptor Antagonists;Igor A. Schepetkin,et al.;《MOLECULAR PHARMACOLOGY》;20110130;第79卷(第1期);参见第82页表2，第83页表3 *
Potent hFPRL1 (ALXR) agonists as potential;Roland W,et al.;《Bioorganic & Medicinal Chemistry Letters》;20060715;第16卷(第1期);全文 *

Also Published As

Publication number Publication date
US20190153004A1 (en) 2019-05-23
MX393070B (es) 2025-03-24
PH12020500285B1 (en) 2024-02-21
US9850264B2 (en) 2017-12-26
TWI616200B (zh) 2018-03-01
PH12015501858B1 (en) 2015-12-07
BR122017004254A2 (pt) 2019-09-10
IL241012A0 (en) 2015-11-30
ES2835825T3 (es) 2021-06-23
RU2018127997A3 (enExample) 2021-09-16
RU2015136774A (ru) 2017-04-10
US10899780B2 (en) 2021-01-26
EP3795148A1 (en) 2021-03-24
JP2016512193A (ja) 2016-04-25
BR122017004254B1 (pt) 2021-04-13
AU2014225992A1 (en) 2015-09-10
MY207109A (en) 2025-01-30
KR102227201B1 (ko) 2021-03-12
MX2015011593A (es) 2015-12-09
CN105007909A (zh) 2015-10-28
KR20150126610A (ko) 2015-11-12
PH12020500286A1 (en) 2021-02-22
CL2017002527A1 (es) 2018-03-23
NZ710173A (en) 2021-01-29
CA2898301A1 (en) 2014-09-12
ZA201505134B (en) 2024-08-28
EP3795148C0 (en) 2025-06-18
JP6602351B2 (ja) 2019-11-06
NZ751239A (en) 2021-01-29
AU2019226215A1 (en) 2019-09-26
JP2018009012A (ja) 2018-01-18
CN110279684A (zh) 2019-09-27
IL273208A (en) 2020-04-30
IL263314B (en) 2020-03-31
EP2964213A1 (en) 2016-01-13
MX364916B (es) 2019-05-13
ES3036990T3 (en) 2025-09-26
PH12020500285A1 (en) 2021-02-22
JP6496786B2 (ja) 2019-04-03
JP6672500B2 (ja) 2020-03-25
AU2018203719B2 (en) 2019-08-29
CN105007909B (zh) 2019-06-28
CA3133264A1 (en) 2014-09-12
US20170320897A1 (en) 2017-11-09
EP2964213B1 (en) 2020-11-04
SG11201507113RA (en) 2015-10-29
TW201517900A (zh) 2015-05-16
JP2017214416A (ja) 2017-12-07
BR112015021371A2 (pt) 2017-07-18
JP2019131569A (ja) 2019-08-08
RU2018127997A (ru) 2018-10-03
US10208071B2 (en) 2019-02-19
CA2898301C (en) 2021-11-16
RU2663911C2 (ru) 2018-08-13
NZ751237A (en) 2021-01-29
IL241012B (en) 2018-12-31
AU2018203719A1 (en) 2018-06-21
AR095034A1 (es) 2015-09-16
WO2014138037A1 (en) 2014-09-12
CL2017002526A1 (es) 2018-05-18
CL2015002485A1 (es) 2016-04-01
KR20200100871A (ko) 2020-08-26
KR102290134B1 (ko) 2021-08-17
BR112015021371B1 (pt) 2021-04-13
EP3795148B1 (en) 2025-06-18
AU2014225992B2 (en) 2018-03-22
SG10201801471RA (en) 2018-04-27
PH12015501858A1 (en) 2015-12-07
HK1219657A1 (zh) 2017-04-13
RU2768730C2 (ru) 2022-03-24
NZ751236A (en) 2021-01-29
AU2019226215B2 (en) 2021-07-29
US20140256684A1 (en) 2014-09-11
JP6196327B2 (ja) 2017-09-13
IL263314A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
CN110279684B (zh) 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
HK40014878B (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
HK40014878A (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
HK40045091A (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
NZ751237B2 (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
NZ710173B2 (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
HK1219657B (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014878

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant